Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2014-07-11 Earnings Release
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 98% confidence The document explicitly announces the "revenue for the 2nd quarter of 2014" and provides a summary income statement for Q2 2014 and H1 2014. This content structure—presenting key financial figures for a specific, shorter reporting period (quarterly)—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), as it focuses on the immediate release of period results rather than a full statutory filing. The document is short and presents highlights, fitting the ER definition better than the comprehensive IR definition. Q2 2014
2014-07-11 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of June 30, 2014. This content directly relates to changes in the company's share capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it reports on the total number of shares outstanding. While it is a regulatory filing, SHA is more specific than the general RNS fallback. It is not a Director's Dealing (DIRS) as it reports total capital, not individual transactions, nor is it a Major Shareholding Notification (MRQ) which reports changes crossing specific thresholds by external parties.
2014-07-03 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT" (Semi-annual report on the liquidity contract with Gilbert Dupont Stock Brokerage). It provides a snapshot of the liquidity account balance as of June 30, 2014, comparing it to the previous annual balance (December 31, 2013). This type of regular, short update concerning financial arrangements, often related to market making or share stabilization, fits best under a general financial update or regulatory filing category. Since it is a specific, periodic report on a financial mechanism (liquidity contract) and not a comprehensive quarterly report (IR), earnings release (ER), or a general regulatory announcement (RNS), it requires careful classification. Given the options, it is a specific financial disclosure. It is not a full Interim Report (IR) as it only covers the liquidity contract. It is not a Dividend Notice (DIV) or Capital Change (CAP). It is a specific financial disclosure related to market operations. The closest fit among the specific financial categories is difficult, but it is a periodic financial disclosure. Since it is a 'Bilan Semestriel' (Semi-annual report) on a specific financial contract, and not a comprehensive financial statement, it is most appropriately categorized as a general Regulatory Filing (RNS) or potentially a specialized financial update. Given the nature of reporting on liquidity contracts, which are often mandatory disclosures, RNS (Regulatory Filings) serves as the best general fit for specific, non-standard financial disclosures that don't match IR, ER, or CAP.
2014-07-02 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 90% confidence The document is a press release dated June 17, 2014, announcing that Nanobiotix has been selected to join the CAC® PME index. This type of announcement, which concerns the company's listing status and market visibility, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate actions (like DIV, SHA, CAP). It is a general corporate update related to market presence and investor relations. Since it is a specific, non-standard announcement that doesn't match the other defined categories (AGM-R, MANG, DIRS, etc.), the most appropriate classification is the general regulatory/miscellaneous filing category, RNS (Regulatory Filings), as it serves as a broad announcement category for items not covered elsewhere.
2014-06-17 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of May 31, 2014. This content directly relates to reporting changes in share capital and voting rights, which aligns with the definition of Major Shareholding Notification (MRQ) or potentially a specific regulatory filing. However, the core content is a mandatory monthly disclosure of the total share count and voting rights, which is a specific type of regulatory disclosure often tracked separately. Given the options, this type of mandatory disclosure about the capital structure and voting rights is most closely related to notifications concerning significant share ownership changes or capital structure updates. Since it is a formal, periodic disclosure about the total number of shares and voting rights, it fits best under Major Shareholding Notification (MRQ) as it directly impacts the calculation of ownership thresholds, or potentially a general Regulatory Filing (RNS). Since the document explicitly details the total number of shares and voting rights, which is a key component of major shareholding disclosures, MRQ is a strong candidate. However, the specific nature of reporting the *total* capital structure monthly often falls under general regulatory reporting if a more specific code isn't available. Let's re-evaluate the definitions. MRQ is for *changes* in significant ownership levels (crossing thresholds). This document reports the *total* capital structure, which is a prerequisite for threshold calculations. Given the French regulatory context (AMF), this specific monthly report on total voting rights is a standard disclosure. If we must choose from the provided list, and it's not a general announcement (RPA/RNS), the closest fit related to share structure is MRQ, although it's not strictly a threshold crossing. Since it is a formal, required regulatory disclosure that is not a full report (10-K, IR) or an earnings release (ER), and it deals with share structure, MRQ is the most specific fit among the choices related to share structure/ownership reporting, even if it's the baseline data. If MRQ is too specific for the baseline total, RNS (Regulatory Filings) is the fallback. Given the highly specific nature of the content (total voting rights calculation), I will classify it as MRQ as it pertains to the underlying data for major shareholding notifications, or RNS if it's considered a general regulatory update. Since it is a formal, periodic regulatory filing about the capital base, RNS is the safest general regulatory classification if MRQ is reserved strictly for threshold breaches. Given the options, and the document being a formal regulatory disclosure about the capital base, RNS is the most appropriate general regulatory filing category when a more specific one (like SHA for new issues) doesn't perfectly match the periodic nature of this report.
2014-06-05 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 99% confidence The document explicitly announces the 'Chiffre d'affaires du premier trimestre 2014' (First Quarter 2014 Revenue) and provides key financial figures for that period. This content aligns perfectly with the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). Although it also mentions a capital increase and shareholder structure changes, the primary focus and headline relate to the quarterly revenue announcement. It is not a comprehensive report (like IR or 10-K), nor is it a transcript (CT) or a formal proxy statement (PSI). The document length (5550 chars) is substantial enough to be the release itself, not just a brief announcement of a release (RPA/RNS). Q1 2014
2014-05-12 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.